Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06050707 · ClinicalTrials.gov registry record · Phase 2
MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach
A Phase 2 study of Anal Squamous Cell Carcinoma, sponsored by University Health Network, Toronto.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 4
- Study locations
NCT06050707 is a Phase 2 study of Anal Squamous Cell Carcinoma that is actively recruiting participants, run by University Health Network, Toronto. The registered enrollment target is 80 participants, roughly in line with the 77-participant average among 5 other Anal Squamous Cell Carcinoma trials with a reported enrollment target. The trial reports 4 study locations across 4 states.
The verdict
NCT06050707, a Phase 2 study of Anal Squamous Cell Carcinoma, is actively recruiting participants, sponsored by University Health Network, Toronto.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 4
- Study locations
Study Summary
The proposed study is a phase II, single arm, open-label trial of MR-guided radiation therapy (RT) with risk stratified RT dose selection in patients with anal cancer. Based on previous data, a risk adaptive treatment approached is proposed in 4 groups: Low risk, standard risk, intermediate risk, and high risk. Human papillomavirus (HPV) DNA will be analyzed to identify novel biomarkers that predict chemoradiotherapy (CRT) response and toxicity.
Conditions Studied
Interventions
- RADIATION Radiotherapy - Low risk group
- RADIATION Radiotherapy - Standard risk group
- RADIATION Radiotherapy - Intermediate risk group
- RADIATION Radiotherapy - High risk group
Study Locations (4)
Pennsylvania
- Allegheny Health Network - Pittsburgh
Wisconsin
- Medical College of Wisconsin Cancer Center - Milwaukee
Victoria
- Austin Health - Heidelberg
Ontario
- Princess Margaret Cancer Centre - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2023-09-29 |
| Est. Completion | 2028-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06050707
The ClinicalTrials.gov registry entry for NCT06050707 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 77-participant average among 5 other Anal Squamous Cell Carcinoma trials with a reported enrollment target. The listed sponsor is University Health Network, Toronto, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Anal Squamous Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Radiotherapy - Low risk group is the first listed.
NCT06050707 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Pennsylvania, Wisconsin, Victoria.
Frequently Asked Questions
What is clinical trial NCT06050707 about?
NCT06050707 is a clinical study titled "MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach". The proposed study is a phase II, single arm, open-label trial of MR-guided radiation therapy (RT) with risk stratified RT dose selection in patients with anal cancer. Based on previous data, a risk adaptive treatment approached is proposed in 4 groups: Low risk, standard risk, intermediate risk, an...
What is the current status of trial NCT06050707?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2023-09-29. Estimated completion is 2028-09-01.
What conditions does trial NCT06050707 study?
This clinical trial studies the following conditions: Anal Squamous Cell Carcinoma.
What interventions are being tested in trial NCT06050707?
The interventions under investigation include: Radiotherapy - Low risk group (RADIATION), Radiotherapy - Standard risk group (RADIATION), Radiotherapy - Intermediate risk group (RADIATION), Radiotherapy - High risk group (RADIATION).
Who is sponsoring clinical trial NCT06050707?
This trial is sponsored by University Health Network, Toronto, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06050707 being conducted?
This trial has 4 study locations across Pennsylvania, Wisconsin, Victoria, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anal Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
RECRUITING · Phase 2
-
Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection
ACTIVE NOT RECRUITING · Phase 2
-
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
RECRUITING · Phase 1
-
Adaptive Radiation in Anal Cancer
RECRUITING · NA
-
A Phase 1 Study in Participants With Advanced Cancer
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.